Medical Sciences
OPEN ACCESS
Main Role Of Morphogenetic Between Fgf-23 And Sklotho In The Development Of Herdic And Vasicular Models In Chronic Key Disease Patients
DOI
Crossref DOI
10.37547/TAJMSPR/Volume03Issue04-18
tajmspr
2021
VOL. 3
/ NO. 04
APRIL
RESEARCH OVERVIEW
Abstract
Diabetes is a major cause of chronic kidney disease (CKD). Poor blood sugar control accelerates the progression of CKD to terminal renal failure. Chronic kidney disease is also an important co-morbidity of diabetes. Impaired renal function further increases the risk of cardiovascular events in diabetic patients and ultimately carries a severe social and economic burden. Altered fibroblast growth factor 23 (FGF-23) and Klotho levels are considered the earliest biochemical abnormality of chronic kidney disease, the mineral and bone disease syndrome.
RESEARCH TOPICS
Keywords
Cardiovascular disease
chronic kidney disease
Downloads
Download data is not yet available.
SOURCES & SCHOLARSHIP
References
- McCullough P.A., Assad H. Diagnosis of cardiovascular disease in patien
- ts with chronic kidney disease//Blood. Purif. – 2012. – Vol. 33(1-3). – P. 112-118.
- . Моисеев В.С., Мухин Н.А., Смирнов А.В. и соавт. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции//Российский кардиологический журнал. – 2014. - № 8. – С.7-37.
- . Mendoza J.M., Isakova T., Cai X., Bayes L.Y., Faul C., Scialla J. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease // Kidney Int. – 2017. – V. 91. – I.3. – P. 711-719.
- . Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N. Engl. J. Med. – 2004. –Vol. 351. – P. 1296–1305 [PubMed]
- . Foley R., Murray A.M., Li S. et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999//J. Наукаожизнииздоровье №2, 2019 34 Am. Soc. Nephrol. – 2005. – Vol. 16 (2). – P. 489 – 495.
- . Kestenbaum B., Sampson J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am SocNephrol. 2005; 16(2):520–528.
- . McGovern A.P., de Lusignan S., van Vlymen J. et al. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One. 2013; 8(9): e74996
- . Kendrick J., KestenbaumВ. ChoncholМ. Phosphate and cardiovascular disease. Adv Chronic Kidney Dis. 2011; 18 (2):113 – 119.
- Moe S.М. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) / Moe S., Drueke T., Cunningham J. et al. // Kidney Int. – 2006. – Vol. 69. – P. 945-1953.